2022
DOI: 10.1016/j.stem.2022.07.004
|View full text |Cite
|
Sign up to set email alerts
|

Direct chemical reprogramming of human cord blood erythroblasts to induced megakaryocytes that produce platelets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
27
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
3

Relationship

1
5

Authors

Journals

citations
Cited by 15 publications
(30 citation statements)
references
References 85 publications
3
27
0
Order By: Relevance
“…According to their expression level, the cell populations can be primarily classified into three clusters. In addition, both FLI1 and KLF1 are highly expressed in the intermediate cell population suspected to be the progenitors of iMKs and EBs [96]. Namely, the pattern of expression level is concordant with the OO motif in our framework (Fig6.D).…”
Section: Section 6: the Chemical-induced Reprogramming Of Human Eryth...supporting
confidence: 77%
See 3 more Smart Citations
“…According to their expression level, the cell populations can be primarily classified into three clusters. In addition, both FLI1 and KLF1 are highly expressed in the intermediate cell population suspected to be the progenitors of iMKs and EBs [96]. Namely, the pattern of expression level is concordant with the OO motif in our framework (Fig6.D).…”
Section: Section 6: the Chemical-induced Reprogramming Of Human Eryth...supporting
confidence: 77%
“…Circle size indicates the sum of in-degree and out-degree. Node colors indicate different Supermodules (adapted from [96]). Green and red edges indicate activation and inhibition, respectively.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…However, the on‐demand application of platelet transfusion is often limited by the low stock availability and the short shelf life of platelets (PLTs) 2 . There exists an alternative strategy to ex vivo engineered manufacturing of induced PLTs or their precursor megakaryocytes (MKs) from stem cell differentiation or somatic cell reprogramming strategies 3,4 . Accumulated evidence indicates that stem cell‐derived MKs or PLTs can be developed as advanced therapeutic and medicinal products for patients with thrombocytopenia 4–7 …”
Section: Introductionmentioning
confidence: 99%